Legend Biotech (LEGN) Net Cash Flow (2019 - 2026)

Legend Biotech (LEGN) has 8 years of Net Cash Flow data on file, last reported at -$254.3 million in Q1 2026.

• Quarterly Net Cash Flow fell 265.56% year-over-year to -$254.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $201.3 million (up 144.18% YoY) and the FY2025 annual result came in at $609.1 million, up 161.59% from the prior year.
• Net Cash Flow retreated to -$254.3 million in Q1 2026, from $625.7 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $625.7 million in Q4 2025 to a low of -$696.3 million in Q2 2024.
• A 5-year average of -$2.6 million and a median of -$25.6 million in 2022 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2022 — Net Cash Flow slumped 611.55% — and 2023, when it surged 19899.89%.
• Tracing LEGN's Net Cash Flow over 5 years: stood at -$25.6 million in 2022, then jumped by 1322.17% to $312.8 million in 2023, then sank by 154.45% to -$170.3 million in 2024, then jumped by 467.41% to $625.7 million in 2025, then sank by 140.64% to -$254.3 million in 2026.
• The last three Net Cash Flow figures came in at -$254.3 million (Q1 2026), $625.7 million (Q4 2025), and $9.5 million (Q3 2025), per Business Quant data.